Refludan (Lepirudin) - Summary

REFLUDAN SUMMARY

REFLUDAN [lepirudin (rDNA) for injection] is a highly specific direct inhibitor of thrombin. Lepirudin (chemical designation: [Leu¹, Thr²]-63-desulfohirudin) is a recombinant hirudin derived from yeast cells.

REFLUDAN is indicated for anticoagulation in patients with heparin-induced thrombocytopenia (HIT) and associated thromboembolic disease in order to prevent further thromboembolic complications.

REFLUDAN NEWS HIGHLIGHTS

Published Studies Related to Refludan (Lepirudin)

Point of care measurement of lepirudin and heparin anticoagulation during systemic inflammation. [2002.10.01]

Lepirudin blunts endotoxin-induced coagulation activation. [2000.03.01]

Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial. [1999.10]

Lepirudin for anticoagulation in patients with heparin-induced thrombocytopenia treated with continuous renal replacement therapy. [2007.05]

Severe anaphylactic reaction after repeated intermittent exposure to lepirudin. [2007.05]

more>>

Clinical Trials Related to Refludan (Lepirudin)

Lepirudin in Treating Patients With Recurrent or Advanced Small Cell Lung Cancer [Active, not recruiting]

Heparin Versus Lepirudin Flushes in Preventing Blockage of Venous Access Devices [Completed]

Fondaparinux in Patients With Acute HIT [Recruiting]

more>>